Related Experiment Video

Updated: Sep 15, 2025

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

18.2K

Congenital myasthenic syndromes

Sally Spendiff1, Hanns Lochmüller2, Ricardo A Maselli3

  • 1Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.

International Review of Neurobiology
|July 17, 2025
PubMed

Insights

Congenital myasthenic syndromes (CMS) are genetic disorders affecting neuromuscular junctions. Accurate diagnosis is crucial for tailored treatment, guiding clinicians toward effective management strategies.

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Congenital myasthenic syndromes (CMS) arise from genetic defects impacting neuromuscular transmission.
  • These genetic mutations affect the neuromuscular junction (NMJ), leading to varied clinical presentations.

Purpose of the Study:

  • To review diagnostic methods for CMS.
  • To differentiate CMS from mimic conditions.
  • To guide clinicians in identifying causative mutations and discuss treatments.

Main Methods:

  • Review of diagnostic tests for CMS.
  • Analysis of clinical and diagnostic findings.
  • Summary of current and emerging therapeutic options.

Main Results:

  • CMS diagnosis requires identifying specific genetic mutations affecting the NMJ.
  • Clinical presentation and prognosis vary based on the genetic defect.
  • Accurate diagnosis is essential for personalized therapeutic management.

Conclusions:

  • Diagnostic approaches for CMS are critical for patient care.
  • Understanding genetic underpinnings guides treatment selection.
  • Emerging therapies offer hope for improved outcomes in CMS patients.
Keywords:
Congenital myasthenic syndromesDiagnosticsGenetic testingNeuromuscular disordersNeuromuscular junction

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.5K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.2K
Muscle Contraction01:10

Muscle Contraction

In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
7.0K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
245